



P.O. Box 147  
8026 East Marlboro Road  
Farmville, NC 27828  
—  
**INTL** +1 252-753-7111  
**USA** (800) 227-6637  
—  
**FAX** (252) 753-3882  
—  
info@cmppharma.com  
cmppharma.com

Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609

June 28, 2023

Sent via E-mail: [AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

Subject: New Drug Introduction Notification pursuant to 18 V.S.A. § 4637(c) and (d)

To the Office of the Attorney General of Vermont:

On 06/14/2023, and pursuant to 18 V.S.A. § 4637(b), CMP PHARMPA, INC., ("CMP") provided to the State of Vermont new drug notice(s) for LIQREV (NDC 46287-0055-01).

LIQREV - (sildenafil) became commercially available on 06/12/2023.

CMP's interpretation of the phrase "introduction of a new prescription drug to market" is to mean when the product is available for purchase.

Pursuant to 18 V.S.A. § 4637(c), and pertaining to LIQREV, CMP submits the following additional information:

**1. US and International marketing and pricing plans used at launch:**

LIQREV will be promoted by our sales force to healthcare professionals to educate them on our product. We will use various means of promotion including in-office visits, ad campaigns, and multimedia marketing. Pricing was established by a comprehensive review to reflect the competitive market, years of product development investments, and various operational costs.



P.O. Box 147  
8026 East Marlboro Road  
Farmville, NC 27828  
—  
**INTL** +1 252-753-7111  
**USA** (800) 227-6637  
—  
**FAX** (252) 753-3882  
—  
info@cmppharma.com  
cmppharma.com

**2. Estimated volume of patients who may be prescribed the drug:**

The estimated number of patients that will be prescribed LIQREV is 130 per month for the remainder of 2023; and 250 per month in 2024.

**3. Whether the FDA granted breakthrough therapy designation or priority review:**

LIQREV did not receive priority review or breakthrough status.

**4. Date and price of acquisition:**

CMP did not acquire LIQREV.

If you have any further questions, please do not hesitate to contact me.

Regards,

Brad Barger  
CFO  
brad.barger@cmppharma.com  
800-227-6637